Review



human p75 ecd standard  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems human p75 ecd standard
    Baseline biomarker data.
    Human P75 Ecd Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+p75+ecd+standard/pmc11415817-217-0-6?v=R%26D+Systems
    Average 94 stars, based on 7 article reviews
    human p75 ecd standard - by Bioz Stars, 2026-07
    94/100 stars

    Images

    1) Product Images from "Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis"

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    Journal: eBioMedicine

    doi: 10.1016/j.ebiom.2024.105323

    Baseline biomarker data.
    Figure Legend Snippet: Baseline biomarker data.

    Techniques Used: Biomarker Discovery, Clinical Proteomics

    Longitudinal biomarker trajectories.
    Figure Legend Snippet: Longitudinal biomarker trajectories.

    Techniques Used: Biomarker Discovery

    Longitudinal biomarker trajectories . Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75 ECD . Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75 ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to <xref ref-type=Table 3 for detailed explanation). " title="... serum NfL; (b) serum pNfH; and (c) urinary p75 ECD . Y-axis shows percent change in each ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Longitudinal biomarker trajectories . Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75 ECD . Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75 ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).

    Techniques Used: Biomarker Discovery

    Prognostic markers of survival.
    Figure Legend Snippet: Prognostic markers of survival.

    Techniques Used: Marker, Diagnostic Assay, Clinical Proteomics

    Baseline prognostic markers of functional decline.
    Figure Legend Snippet: Baseline prognostic markers of functional decline.

    Techniques Used: Functional Assay, Marker, Diagnostic Assay, Clinical Proteomics

    Estimated total sample size savings in a random slopes model of ALSFRS-R progression that includes the prognostic marker and covariate(s).
    Figure Legend Snippet: Estimated total sample size savings in a random slopes model of ALSFRS-R progression that includes the prognostic marker and covariate(s).

    Techniques Used: Marker, Clinical Proteomics



    Similar Products

    human p75 ecd standard  (R&D Systems)
    94
    R&D Systems human p75 ecd standard
    Baseline biomarker data.
    Human P75 Ecd Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+p75+ecd+standard/pmc11415817-217-0-6?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    human p75 ecd standard - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    recombinant human p75 ecd standard  (R&D Systems)
    93
    R&D Systems recombinant human p75 ecd standard
    Urinary <t>p75</t> <t>ECD</t> levels are higher in patients with ALS (n = 54) than in controls (n = 45) at first study visit ( p < 0.0001, 2-sample t test).
    Recombinant Human P75 Ecd Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+p75+ecd+standard/pmc05373786-25-3-11?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    recombinant human p75 ecd standard - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Baseline biomarker data.

    Journal: eBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Baseline biomarker data.

    Article Snippet: Human p75 ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Biomarker Discovery, Clinical Proteomics

    Longitudinal biomarker trajectories.

    Journal: eBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Longitudinal biomarker trajectories.

    Article Snippet: Human p75 ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Biomarker Discovery

    Longitudinal biomarker trajectories . Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75 ECD . Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75 ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to <xref ref-type=Table 3 for detailed explanation). " width="100%" height="100%">

    Journal: eBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Longitudinal biomarker trajectories . Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75 ECD . Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75 ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).

    Article Snippet: Human p75 ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Biomarker Discovery

    Prognostic markers of survival.

    Journal: eBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Prognostic markers of survival.

    Article Snippet: Human p75 ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Marker, Diagnostic Assay, Clinical Proteomics

    Baseline prognostic markers of functional decline.

    Journal: eBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Baseline prognostic markers of functional decline.

    Article Snippet: Human p75 ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Functional Assay, Marker, Diagnostic Assay, Clinical Proteomics

    Estimated total sample size savings in a random slopes model of ALSFRS-R progression that includes the prognostic marker and covariate(s).

    Journal: eBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Estimated total sample size savings in a random slopes model of ALSFRS-R progression that includes the prognostic marker and covariate(s).

    Article Snippet: Human p75 ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Marker, Clinical Proteomics

    Urinary p75 ECD levels are higher in patients with ALS (n = 54) than in controls (n = 45) at first study visit ( p < 0.0001, 2-sample t test).

    Journal: Neurology

    Article Title: Urinary p75 ECD

    doi: 10.1212/WNL.0000000000003741

    Figure Lengend Snippet: Urinary p75 ECD levels are higher in patients with ALS (n = 54) than in controls (n = 45) at first study visit ( p < 0.0001, 2-sample t test).

    Article Snippet: Urine samples and recombinant human p75 ECD standard (amino acids 29–250; R&D Systems, Minneapolis, MN) were diluted in sample buffer and incubated for 20 hours at room temperature.

    Techniques:

    (A) Individual patient urinary p75 ECD trajectories increase since time of diagnosis at an average rate of 0.19 ng/mg creatinine per month (95% confidence interval [CI] 0.15–0.24). (B) p75 ECD trajectories also increase since time from symptom onset (0.18 ng/mg, 95% CI 0.13–0.22), and (C) time since the initial evaluation and sample collection (i.e., baseline) (0.20 ng/mg, 95% CI 0.15–0.25). Total 31 patients with ALS, each sampled at least twice.

    Journal: Neurology

    Article Title: Urinary p75 ECD

    doi: 10.1212/WNL.0000000000003741

    Figure Lengend Snippet: (A) Individual patient urinary p75 ECD trajectories increase since time of diagnosis at an average rate of 0.19 ng/mg creatinine per month (95% confidence interval [CI] 0.15–0.24). (B) p75 ECD trajectories also increase since time from symptom onset (0.18 ng/mg, 95% CI 0.13–0.22), and (C) time since the initial evaluation and sample collection (i.e., baseline) (0.20 ng/mg, 95% CI 0.15–0.25). Total 31 patients with ALS, each sampled at least twice.

    Article Snippet: Urine samples and recombinant human p75 ECD standard (amino acids 29–250; R&D Systems, Minneapolis, MN) were diluted in sample buffer and incubated for 20 hours at room temperature.

    Techniques: Biomarker Discovery

    (A) Using p75 ECD measures from all 115 person-visits, urinary p75 ECD correlates with ALSFRS-R ( r = −0.36, p < 0.0001). After adjusting for the within-person correlation that arises from repeated measures of the longitudinal subset, the correlation remains essentially unchanged ( r = −0.37). (B) Urinary p75 ECD also correlates with ALSFRS-R at first study visit for each of the 54 patients with amyotrophic lateral sclerosis in the study ( r = −0.44, p = 0.008).

    Journal: Neurology

    Article Title: Urinary p75 ECD

    doi: 10.1212/WNL.0000000000003741

    Figure Lengend Snippet: (A) Using p75 ECD measures from all 115 person-visits, urinary p75 ECD correlates with ALSFRS-R ( r = −0.36, p < 0.0001). After adjusting for the within-person correlation that arises from repeated measures of the longitudinal subset, the correlation remains essentially unchanged ( r = −0.37). (B) Urinary p75 ECD also correlates with ALSFRS-R at first study visit for each of the 54 patients with amyotrophic lateral sclerosis in the study ( r = −0.44, p = 0.008).

    Article Snippet: Urine samples and recombinant human p75 ECD standard (amino acids 29–250; R&D Systems, Minneapolis, MN) were diluted in sample buffer and incubated for 20 hours at room temperature.

    Techniques:

    Kaplan-Meier survival estimates comparing 27 patients with amyotrophic lateral sclerosis who had baseline urinary p75 ECD above (red dashed line) and 27 with values below (black line) the median (5.3 ng/mg creatinine), illustrates the longer median survival in those with lower compared to higher urinary p75 ECD levels (13.9 vs 8.9 months; Wilcoxon test p = 0.024).

    Journal: Neurology

    Article Title: Urinary p75 ECD

    doi: 10.1212/WNL.0000000000003741

    Figure Lengend Snippet: Kaplan-Meier survival estimates comparing 27 patients with amyotrophic lateral sclerosis who had baseline urinary p75 ECD above (red dashed line) and 27 with values below (black line) the median (5.3 ng/mg creatinine), illustrates the longer median survival in those with lower compared to higher urinary p75 ECD levels (13.9 vs 8.9 months; Wilcoxon test p = 0.024).

    Article Snippet: Urine samples and recombinant human p75 ECD standard (amino acids 29–250; R&D Systems, Minneapolis, MN) were diluted in sample buffer and incubated for 20 hours at room temperature.

    Techniques: